Health care resource use and direct medical costs for patients with schizophrenia in Tianjin, People’s Republic of China

Jing Wu,1 Xiaoning He,1 Li Liu,2 Wenyu Ye,2 William Montgomery,3 Haibo Xue,2 Jeffery S McCombs41School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, People’s Republic of China; 2Lilly Suzhou Pharmaceutical Company, Ltd, Shanghai, People’s Republic of Chi...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Wu J, He XN, Liu L, Ye W, Montgomery W, Xue HB, McCombs JS
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2015
Materias:
Acceso en línea:https://doaj.org/article/994b8b9fe6ee499f97fdede25ff38b19
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:994b8b9fe6ee499f97fdede25ff38b19
record_format dspace
spelling oai:doaj.org-article:994b8b9fe6ee499f97fdede25ff38b192021-12-02T07:18:08ZHealth care resource use and direct medical costs for patients with schizophrenia in Tianjin, People’s Republic of China1178-2021https://doaj.org/article/994b8b9fe6ee499f97fdede25ff38b192015-04-01T00:00:00Zhttp://www.dovepress.com/health-care-resource-use-and-direct-medical-costs-for-patients-with-sc-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021 Jing Wu,1 Xiaoning He,1 Li Liu,2 Wenyu Ye,2 William Montgomery,3 Haibo Xue,2 Jeffery S McCombs41School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, People’s Republic of China; 2Lilly Suzhou Pharmaceutical Company, Ltd, Shanghai, People’s Republic of China; 3Eli Lilly and Company, Sydney, Australia; 4Departments of Clinical Pharmacy and Pharmaceutical Economics and Policy, School of Pharmacy, University of Southern California, Los Angeles, CA, USAObjective: Information concerning the treatment costs of schizophrenia is scarce in People’s Republic of China. The aims of this study were to quantify health care resource utilization and to estimate the direct medical costs for patients with schizophrenia in Tianjin, People’s Republic of China.Methods: Data were obtained from the Tianjin Urban Employee Basic Medical Insurance (UEBMI) database. Adult patients with ≥1 diagnosis of schizophrenia and 12-month continuous enrollment after the first schizophrenia diagnosis between 2008 and 2009 were included. Both schizophrenia-related, psychiatric-related, and all-cause related resource utilization and direct medical costs were estimated.Results: A total of 2,125 patients were included with a mean age of 52.3 years, and 50.7% of the patients were female. The annual mean all-cause costs were $2,863 per patient with psychiatric-related and schizophrenia-related costs accounting for 84.1% and 62.0% respectively. The schizophrenia-related costs for hospitalized patients were eleven times greater than that of patients who were not hospitalized. For schizophrenia-related health services, 60.8% of patients experienced at least one hospitalization with a mean (median) length of stay of 112.1 (71) days and a mean cost of $1,904 per admission; 59.0% of patients experienced at least one outpatient visit with a mean (median) number of visits of 6.2 (4) and a mean cost of $42 per visit during the 12-month follow-up period. Non-medication treatment costs were the most important element (45.7%) of schizophrenia-related costs, followed by laboratory and diagnostic costs (19.9%), medication costs (15.4%), and bed fees (13.3%).Conclusion: The costs related to the treatment of patients with schizophrenia were considerable in Tianjin, People’s Republic of China, driven mainly by schizophrenia-related hospitalizations. Efforts focusing on community-based treatment programs and appropriate choice of drug treatment have the potential to reduce the use of inpatient services and may lead to better clinical and economic outcomes in the management of patients with schizophrenia in People’s Republic of China.Keywords: schizophrenia, health care resource use, direct medical costs, People’s Republic of ChinaWu JHe XNLiu LYe WMontgomery WXue HBMcCombs JSDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2015, Iss default, Pp 983-990 (2015)
institution DOAJ
collection DOAJ
language EN
topic Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
spellingShingle Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
Wu J
He XN
Liu L
Ye W
Montgomery W
Xue HB
McCombs JS
Health care resource use and direct medical costs for patients with schizophrenia in Tianjin, People’s Republic of China
description Jing Wu,1 Xiaoning He,1 Li Liu,2 Wenyu Ye,2 William Montgomery,3 Haibo Xue,2 Jeffery S McCombs41School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, People’s Republic of China; 2Lilly Suzhou Pharmaceutical Company, Ltd, Shanghai, People’s Republic of China; 3Eli Lilly and Company, Sydney, Australia; 4Departments of Clinical Pharmacy and Pharmaceutical Economics and Policy, School of Pharmacy, University of Southern California, Los Angeles, CA, USAObjective: Information concerning the treatment costs of schizophrenia is scarce in People’s Republic of China. The aims of this study were to quantify health care resource utilization and to estimate the direct medical costs for patients with schizophrenia in Tianjin, People’s Republic of China.Methods: Data were obtained from the Tianjin Urban Employee Basic Medical Insurance (UEBMI) database. Adult patients with ≥1 diagnosis of schizophrenia and 12-month continuous enrollment after the first schizophrenia diagnosis between 2008 and 2009 were included. Both schizophrenia-related, psychiatric-related, and all-cause related resource utilization and direct medical costs were estimated.Results: A total of 2,125 patients were included with a mean age of 52.3 years, and 50.7% of the patients were female. The annual mean all-cause costs were $2,863 per patient with psychiatric-related and schizophrenia-related costs accounting for 84.1% and 62.0% respectively. The schizophrenia-related costs for hospitalized patients were eleven times greater than that of patients who were not hospitalized. For schizophrenia-related health services, 60.8% of patients experienced at least one hospitalization with a mean (median) length of stay of 112.1 (71) days and a mean cost of $1,904 per admission; 59.0% of patients experienced at least one outpatient visit with a mean (median) number of visits of 6.2 (4) and a mean cost of $42 per visit during the 12-month follow-up period. Non-medication treatment costs were the most important element (45.7%) of schizophrenia-related costs, followed by laboratory and diagnostic costs (19.9%), medication costs (15.4%), and bed fees (13.3%).Conclusion: The costs related to the treatment of patients with schizophrenia were considerable in Tianjin, People’s Republic of China, driven mainly by schizophrenia-related hospitalizations. Efforts focusing on community-based treatment programs and appropriate choice of drug treatment have the potential to reduce the use of inpatient services and may lead to better clinical and economic outcomes in the management of patients with schizophrenia in People’s Republic of China.Keywords: schizophrenia, health care resource use, direct medical costs, People’s Republic of China
format article
author Wu J
He XN
Liu L
Ye W
Montgomery W
Xue HB
McCombs JS
author_facet Wu J
He XN
Liu L
Ye W
Montgomery W
Xue HB
McCombs JS
author_sort Wu J
title Health care resource use and direct medical costs for patients with schizophrenia in Tianjin, People’s Republic of China
title_short Health care resource use and direct medical costs for patients with schizophrenia in Tianjin, People’s Republic of China
title_full Health care resource use and direct medical costs for patients with schizophrenia in Tianjin, People’s Republic of China
title_fullStr Health care resource use and direct medical costs for patients with schizophrenia in Tianjin, People’s Republic of China
title_full_unstemmed Health care resource use and direct medical costs for patients with schizophrenia in Tianjin, People’s Republic of China
title_sort health care resource use and direct medical costs for patients with schizophrenia in tianjin, people’s republic of china
publisher Dove Medical Press
publishDate 2015
url https://doaj.org/article/994b8b9fe6ee499f97fdede25ff38b19
work_keys_str_mv AT wuj healthcareresourceuseanddirectmedicalcostsforpatientswithschizophreniaintianjinpeoplersquosrepublicofchina
AT hexn healthcareresourceuseanddirectmedicalcostsforpatientswithschizophreniaintianjinpeoplersquosrepublicofchina
AT liul healthcareresourceuseanddirectmedicalcostsforpatientswithschizophreniaintianjinpeoplersquosrepublicofchina
AT yew healthcareresourceuseanddirectmedicalcostsforpatientswithschizophreniaintianjinpeoplersquosrepublicofchina
AT montgomeryw healthcareresourceuseanddirectmedicalcostsforpatientswithschizophreniaintianjinpeoplersquosrepublicofchina
AT xuehb healthcareresourceuseanddirectmedicalcostsforpatientswithschizophreniaintianjinpeoplersquosrepublicofchina
AT mccombsjs healthcareresourceuseanddirectmedicalcostsforpatientswithschizophreniaintianjinpeoplersquosrepublicofchina
_version_ 1718399528348942336